<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347602">
  <stage>Registered</stage>
  <submitdate>19/10/2011</submitdate>
  <approvaldate>21/10/2011</approvaldate>
  <actrnumber>ACTRN12611001095954</actrnumber>
  <trial_identification>
    <studytitle>Treatment of chronic refractory urticaria with the medicine adalimumab</studytitle>
    <scientifictitle>Treatment of chronic refractory urticaria with adalimumab</scientifictitle>
    <utrn>U1111-1125-3242</utrn>
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Urticaria</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment with adalimumab 
Dose: 80 mg at first administration week 0, thereafter 40 mg at week 1+3+5+7+9+11+13+15.
Total duration af treatment is 16 weeks.
The mode of administration is subcutaneous.</interventions>
    <comparator>Uncontrolled study</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Urticaria Activity Score</outcome>
      <timepoint>Baseline and week 4, 9, 16, 18, 20 and 28</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Itch assessed with Structured Itch Questionnaire</outcome>
      <timepoint>Baseline and week 4, 9, 16, 18, 20 and 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Life quality and emotions assessed with Becks Depression Inventory, Brief Symptom Inventory and Dermatology Life Quality Index</outcome>
      <timepoint>Baseline and week 4, 9, 16, 18, 20 and 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sleep quality assessed with Pittsburg Sleep Quality Index</outcome>
      <timepoint>Baseline and week 4, 9, 16, 18, 20 and 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Bodily sensations assessed with Somatosensory Amplification Scale</outcome>
      <timepoint>Baseline and week 4, 9, 16, 18, 20 and 28</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with chronic urticaria. Duration of chronic urticaria more than 6 months with maximum 2 days between urticaria outbreaks. Unsatisfactory treatment with high dose antihistamines, prednisolone and at least one other immunosuppressive drug for at least 3 months. Unsatisfactory treatment is defined as symptoms several times at week despite treatment.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>67</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnancy and lactation
Diabetes Mellitus
Severe heart disease, kidney disease or liver disease
Chronic infections 
Former malignancies except non-melanoma skin cancer
Former treatment with tumour necrosis factor alpha-inhibitors</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/08/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Senior doctor Claus Zachariae</primarysponsorname>
    <primarysponsoraddress>Niels Andersens Vej 65
2900 Hellerup</primarysponsoraddress>
    <primarysponsorcountry>Denmark</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Abbott Denmark</fundingname>
      <fundingaddress>Emdrupvej 28C

2100 Koebenhavn Oe</fundingaddress>
      <fundingcountry>Denmark</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Aage Bang Foundation</fundingname>
      <fundingaddress>Frederiksgade 19, 4
1265 Koebenhavn K</fundingaddress>
      <fundingcountry>Denmark</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to examine, whether patients with longlasting urticaria, where other treatments have been ineffective, will benefit from treatment with the drug adalimumab. The cytokine tumour necrosis factor alfa is upregulated in the skin and serum in patients with urticaria. Adalimumab is a drug, that blocks tumour necrosis factor alfa.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics Committee of the Capital Region of Denmark</ethicname>
      <ethicaddress>Kongens Vaenge 2
3400 Hilleroed</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Denmark</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Claus Zachariae</name>
      <address>Niels Andersens Vej 65
2900 Hellerup</address>
      <phone>+45 3977 3203</phone>
      <fax />
      <email>clza@geh.regionh.dk</email>
      <country>Denmark</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Claus Zachariae</name>
      <address>Niels Andersens Vej 65
2900 Hellerup</address>
      <phone>+45 3977 3203</phone>
      <fax />
      <email>clza@geh.regionh.dk</email>
      <country>Denmark</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>